secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2026-07-08T00:03:50+00:00
Accession:  0001297184-26-000041
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar subsidiary IMS receives FDA warning letter for CGMP violations at South El Monte facility
--------------------------------------------------------------------------------

- Warning letter dated July 2, 2026, follows December 2025 FDA inspection of IMS's South El Monte, CA facility.
- Cites violations of current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.
- FDA does not direct IMS to cease or restrict products from the facility; no further recall required at this time.
- IMS must submit initial response within 15 working days and provide a risk assessment and remediation plan.
- Company is evaluating impact; additional regulatory or legal action possible if deficiencies are not resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000041/0001297184-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000041/amph-20260702x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer